Arbutus Appoints Dr. Frank Torti as Chairman of its Board of Directors
November 26, 2018 16:41 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr....
Arbutus Reports 2018 Third Quarter Financial Results and Provides Corporate Update
November 07, 2018 16:01 ET
|
Arbutus Biopharma Corporation
- AB-506, a second-generation capsid inhibitor, advanced to HBV patient portion of Phase 1a/1b clinical trial - ONPATTRO™ (patisiran) approved by the U.S. Food and Drug Administration (FDA) and the...
Arbutus to Report Third Quarter 2018 Financial Results
October 31, 2018 08:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it...
Arbutus Names New Members to its Board of Directors
October 22, 2018 08:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that James...
Arbutus Provides Update on HBV Development Programs and Announces Appointment of Dr. Gaston Picchio as Chief Development Officer
October 09, 2018 08:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced a change...
Arbutus to Present at Chardan’s Genetic Medicines Conference
October 02, 2018 08:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr....
Arbutus to Participate at the 2018 B. Riley FBR Healthcare Conference
August 28, 2018 08:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr....
Arbutus’ LNP Licensee Alnylam Announces FDA Approval of ONPATTRO™ (patisiran), for the Treatment of ATTR Amyloidosis
August 13, 2018 08:30 ET
|
Arbutus Biopharma Corporation
ONPATTRO Approval Triggers Royalty to Arbutus Clinically Validated LNP Technology Now in the Hands of Genevant to Develop RNA-based Products WARMINSTER, Pa., Aug. 13, 2018 (GLOBE NEWSWIRE) --...
Arbutus to Present at the 2018 Wedbush PacGrow Healthcare Conference
August 09, 2018 08:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr....
Arbutus Reports 2018 Second Quarter Financial Results and Provides Corporate Update
August 02, 2018 16:00 ET
|
Arbutus Biopharma Corporation
- Phase 1a/1b study of AB-506, a second-generation oral capsid inhibitor, initiated - Phase 1a/1b study of AB-452, a novel and proprietary oral RNA destabilizer, expected to begin in the second half...